524404 Stock Overview
Marksans Pharma Limited, together with its subsidiaries, engages in the research and development, manufacturing, marketing, and sale of generic pharmaceutical formulations worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Marksans Pharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹174.40 |
| 52 Week High | ₹185.40 |
| 52 Week Low | ₹70.20 |
| Beta | 1.6 |
| 1 Month Change | 24.35% |
| 3 Month Change | 11.47% |
| 1 Year Change | 122.99% |
| 3 Year Change | 148.43% |
| 5 Year Change | 620.66% |
| Change since IPO | 558.24% |
Recent News & Updates
Recent updates
Shareholder Returns
| 524404 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 7.0% | -2.5% | -2.5% |
| 1Y | 123.0% | 55.2% | 44.5% |
Return vs Industry: 524404 exceeded the Indian Pharmaceuticals industry which returned 55.2% over the past year.
Return vs Market: 524404 exceeded the Indian Market which returned 44.5% over the past year.
Price Volatility
| 524404 volatility | |
|---|---|
| 524404 Average Weekly Movement | 7.3% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in IN Market | 10.1% |
| 10% least volatile stocks in IN Market | 4.3% |
Stable Share Price: 524404 has not had significant price volatility in the past 3 months.
Volatility Over Time: 524404's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 852 | Mark Saldanha | marksanspharma.com |
Marksans Pharma Limited, together with its subsidiaries, engages in the research and development, manufacturing, marketing, and sale of generic pharmaceutical formulations worldwide. The company offers products in the analgesics, benign prostatic hyperplasia, antidiabetic, epilepsy, anti-inflammatory, hyperparathyroidism, diabetes, antacids, neurology, cardiovascular, hormonal, oncology, gastroenterology, antidiabetic, pain management, gynecology, antifungal, antiulceratives, vitamins, dermatology, cephalosporins, injectables, anti-allergy, antibacterial, and hypertension therapeutic areas. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India.
Marksans Pharma Limited Fundamentals Summary
| 524404 fundamental statistics | |
|---|---|
| Market cap | ₹77.24b |
| Earnings (TTM) | ₹3.16b |
| Revenue (TTM) | ₹21.03b |
25.0x
P/E Ratio3.8x
P/S RatioIs 524404 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 524404 income statement (TTM) | |
|---|---|
| Revenue | ₹21.03b |
| Cost of Revenue | ₹10.31b |
| Gross Profit | ₹10.72b |
| Other Expenses | ₹7.56b |
| Earnings | ₹3.16b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 6.98 |
| Gross Margin | 50.99% |
| Net Profit Margin | 15.04% |
| Debt/Equity Ratio | 5.9% |
How did 524404 perform over the long term?
See historical performance and comparison